The purpose of this study is to validate and characterize phenotypes of diabetic retinopathy (DR) progression based on available clinical data (demographic, systemic and ophthalmic data).

This study aims to validate and characterize phenotypes of diabetic retinopathy (DR) progression using ophthalmic and systemic data from type-2 diabetic subjects followed at the AIBILI Clinical Trial Center in the last 10 years.

Macular Edema (ME) development during the study period, mainly Clinically Significant ME (CSME) needing treatment, will be the primary indicator for DR progression. CSME will be considered as the primary end-point and will be used to identify phenotypes (and risk markers) of DR progression.

Inclusion Criteria:

• Diagnosis of DR.
• Females or Males;
• Age over 18 years;
• Signed Informed Consent;
• Previous follow-up with regular systemic and ophthalmic assessments.

Exclusion Criteria:

• Cataract or other eye disease that may interfere with fundus examinations;
• Vitreous syneresis or posterior vitreous detachment;
• Dilatation of the pupil < 5 mm.

Type-2 diabetic subjects diagnosed with DR, followed regularly by their ophthalmologist at the AIBILI Clinical Trial Center, with a previous follow-up in which systemic data and ophthalmological examinations were performed regularly.